Glargine and degludec: Solution behaviour of higher dose synthetic insulins
Abstract Single, double and triple doses of the synthetic insulins glargine and degludec currently used in patient therapy are characterised using macromolecular hydrodynamic techniques (dynamic light scattering and analytical ultracentrifugation) in an attempt to provide the basis for improved pers...
Guardado en:
Autores principales: | Gary G. Adams, Qushmua Alzahrani, Shahwar I. Jiwani, Andrew Meal, Paul S. Morgan, Frank Coffey, Samil Kok, Arthur J. Rowe, Stephen E. Harding, Naomi Chayen, Richard B. Gillis |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2017
|
Materias: | |
Acceso en línea: | https://doaj.org/article/b78d16e655964b44a202114d783230a1 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Analysis of insulin glulisine at the molecular level by X-ray crystallography and biophysical techniques
por: Richard B. Gillis, et al.
Publicado: (2021) -
Is insulin degludec a more effective treatment for patients using high doses of insulin glargine but not attaining euglycemia? Some case reports from India
por: Sinha B, et al.
Publicado: (2014) -
On the safety of insulin Glargine
por: Ivan Ivanovich Dedov, et al.
Publicado: (2009) -
Insulin degludec is a new ultra-long-acting insulin analogue
por: Ivan Ivanovich Dedov, et al.
Publicado: (2014) -
Insulin degludec/insulin aspart is the first co-formulation of basal and prandial insulin analogues
por: Ivan Ivanovich Dedov, et al.
Publicado: (2014)